The National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), awarded a $242,310 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF). This grant, effective July 1, 2024 through November 30, 2026, will support UCSF's research to adapt cell-based therapies for the treatment of pulmonary fibrosis. As a leading academic medical research institution, UCSF...
This $1,147,992 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to advance precision medicine for acute respiratory distress syndrome (ARDS) and sepsis. The research aims to address key unanswered questions about the functional immune response and pathogens driving the hyperinflammatory and hypoinflammatory phenotypes of these conditions, identify potential druggable targets, and...
The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $799,354 to Northwestern University to conduct research on the role of necroptosis, a form of cell death, in primary graft dysfunction (PGD) following lung transplantation. The research aims to comprehensively investigate the contribution of necroptosis pathways in both the recipient's native lungs and the donor lungs to the development...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $144,362 to Brown University to investigate the role of pulmonary natural killer cells in cytomegalovirus (CMV)-induced pneumonitis. The award, effective from June 21, 2024 to January 31, 2027, aims to elucidate the mechanisms of immune control of pulmonary CMV infection and gain insights into the pathogenesis of CMV in humans....
The University of California, San Diego has been awarded a $1,451,467 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the mechanisms governing the development of diverse cardiovascular cell types from juxta-cardiac field progenitors. The 4-year grant, effective July 1, 2024, will employ a multidisciplinary approach including experimental and computational systems biology to: 1) examine the contribution of...
This $197,748 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on low cardiorespiratory fitness and chronotropic incompetence in individuals with HIV. The 5-year project, which began on June 1, 2024, will be conducted by the Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution. The research aims to investigate risk...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $648,534.47 to the University of California, San Diego to conduct research on how senescent lung fibroblasts regulate epithelial regeneration after injury through the senescence-associated secretory phenotype (SASP). The key objectives are to: 1) Determine if alveolar P16INK4A+ fibroblasts can promote epithelial growth after acute injury...
This federal Project Grant award, with ID R01HL177013, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $684,814 award supports research to investigate how lung tissue factors can alter the inflammatory response to viral infections and suppress alveolar stem cells in emphysema, a subtype of chronic obstructive pulmonary disease (COPD). Key objectives include determining the mechanisms by which stromal...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to identify novel transcriptional regulators of endocardial-specific gene expression and understand their role in heart development, homeostasis, and regeneration. The overall project aims to delineate the gene regulatory networks controlling endocardial specification and function. Key objectives include determining how...
This $350,546 project grant from the Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute will support research into natural killer cells and pulmonary ischemia-reperfusion injury. The Regents of the University of California, San Francisco will investigate the role of natural killer cells in primary graft dysfunction following lung transplantation through three specific aims: determining how natural killer cells are activated and induce mouse primary graft dysfunction; establishing how natural killer cells traffic to the lung during primary graft dysfunction in mice; and evaluating natural killer cell activation in human primary graft dysfunction. This work aligns with the stated goals of the Cardiovascular Diseases Research program (CFDA 93.837) to advance heart and vascular research and build a talented investigator pipeline in these areas through competitive training grants. The grant period runs from July 1, 2021 through July 2, 2021.